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Intrarenal prostaglandin release: Effects of arachidonic acid and
hyperchioremia. We measured the release of PGE2, 6kPGF1,, PGF2,,,
and TXB2 into urine (U) and renal hilar lymph (L) to assess the possible
roles of intrarenal prostaglandins (PGs) in arachidonic acid (AA)-
induced renal vasodilation and Cl-induced renal vasoconstriction, (a
model of tubuloglomerular feedback, TG). AA caused an ipsilateral fall
in renal vascular resistance (RVR) and diuresis and increased release of
all PGs into U; release of 6kPGF,,, into L increased ninefold.
Hypertonic NaCI infusion caused ipsilateral vasoconstriction and de-
creased GFR; the release of TXB2 into U and L increased, but other
PGs were not altered consistently. During a background infusion of AA,
hypertonic NaCI infusion again evoked TXB2 release into U and L
without significant changes in other PGs. AA attenuated the NaCI-
induced renal vasoconstriction in dogs with the highest rates of PGE2
release into L. Changes in RVR correlated with the ratio of excretion of
vasodilator PG (PGE2 + 6kPGF1) to TXB2 (r = —0.74). Indomethacin
administration blunted, but did not abolish, the Cl-induced increase in
RVR. In conclusion, (I) AA evokes the release of PGs, especially
prostacyclin, into renal cortex; (2) hyperchloremia increases RVR and
evokes a rather selective release of renal TX; (3) the production of
vasodilator PGs by AA may attenuate Cl-induced renal vasoconstric-
tion; (4) renal vasodilator and vasoconstrictor PGs can be released
relatively independently—their balance could modulate RVR during
activation of the TG response.
Relargage intrarénal de prostaglandines: Effets de l'acide
arachidonique et de l'hyperchlorémie. Nous avons mesuré le relargage
de PGE2, 6kPGF1,,, et TXB2 dans les urines (U) et Ia lymphe (L) hilaire
rénale pour préciser les roles possibles des prostaglandines intrarénales
(PGs) sur Ia vasodilatation rénale induite par l'acide arachidonique
(AA) et sur Ia vasoconstriction rénale induite par Cl (un modéle de
feedback tubulo-glomérulaire, TG). AA a entrainé une chute ipsilatérale
des resistances vasculaires rénales (RVR) et de Ia diurése et a augmentC
le relargage de toutes les PGs dans U; le relargage de 6kPGF1,. dans L
a augmenté de 9 fois. Une perfusion de NaCI hypertonique a entrainé
une vasoconstriction ipsilaterale et a diminué GFR; le relargage de
TXB2 dans U et L a augmente, mais les autres PGs n'étaient pas
notablement modifiées. Au cours d'une perfusion continue d'AA, une
perfusion de NaCI hypertonique a encore entrainé un relargage de TXB2
dans U et L sans changements significatifs des autres PGs. AA a
attCnué Ia vasoconstriction rénale induite par Ic NaCI chez les chiens
ayant les vitesses de relargage de PGE2 dans L les plus grandes. Les
modifications de RVR étaient corrélées au rapport d'excrétion de PG
vasodilatatrices (PGE, + 6kPGF1) sur TXB2 (r = —0,74). L'ad-
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ministration d'indométhacine a diminué, mais n'a pas aboli l'élévation
de RVR induite par Cl. En conclusion, (1) AA entraine un relargage de
PGs, surtout de prostacycline, dans Ic cortex renal; (2) I'hyper-
chlorémie augmente RVR et induit un relargage relativement sélectif de
TX renal; (3) Ia production de PGs vasodilatatrices par AA pourrait
atténuer la vasoconstriction rénale induite par Cl; (4) les PGs
vasodilatatrices et vasoconstrictrices rénales peuvent être relarguees de
facon relativement indépendante. Leur Cquilibre pourrait moduler RVR
au cours de l'activation de Ia response TG.
Infusions of PGE2 or prostacyclin (PGI2) in the dog cause
renal vasodilation and natriuresis [1—5]. There is much evidence
that vasodilator prostaglandiris (PGs) can maintain renal vascu-
lar resistance (RVR) when renal perfusion or extracellular fluid
volume (ECV) is compromised [6—8]. Thus, RVR is increased
after prostaglandin (PG) synthesis is inhibited with indometh-
acm during hemorrhage, hypotension, or salt depletion,
whereas it is reduced after augmenting PG synthesis with
arachidonic acid (AA) [1, 2, 6—8]. On the other hand, during the
hepato-renal syndrome [9], prolonged ureteral ligation [10],
experimental nephritis [11], and angiotensin Il-induced renal
vasoconstriction in hypertensive rats [12], a vasoconstrictor
prostaglandin, thromoboxane (TX), is produced in the kidney
and has been implicated in the accompanying reduction in renal
blood flow (RBF) and/or glomerular filtration rate (GFR).
PGs could affect RVR and GFR by modulating the tubulo-
glomerular feedback response (TG) whereby the blood flow and
GFR of a nephron are related to its rate of chloride (Cl—)
reabsorption at the macula densa segment. Thus, indomethacin
abolished this vasoconstrictive response in the rat, thereby
implicating an increased release of vasoconstrictor PGs or
decreased release of vasodilator PGs [13]. However, this con-
clusion is difficult to reconcile with the finding that the response
was restored by intrarenal infusion of PGE2 or PG!2 [13].
Clearly, it is important to establish the pattern of release of
vasoactive PGs within the kidney during a TG response to
evaluate the role of the PG system. We have developed a
whole-kidney model of TG in the dog in which renal vasocon-
striction and a fall in GFR are evoked by intrarenal infusions of
hypertonic solutions of sodium chloride [14, 15]. This
vasoconstrictive response is specific for the kidney, requires a
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rise in the plasma C1 concentration (Pci), and is abolished by
furosemide [14—16]. We assessed the pattern of release of
vasoactive PGs into the renal cortex during AA-induced renal
vasodilation and Cl-induced renal vasoconstriction. To probe
further the role of PGs in TG, we measured PG release during
hyperchioremia while PG production was augmented by an
intrarenal infusion of arachidonic acid (AA) and assessed the
effects of indomethacin on Cl-induced renal vasoconstriction.
Since lymphatic vessels are distributed to the arterioles, venules, and
glomeruli of the renal cortex [17, 18], we analyzed the hormone
content of renal lymph as well as urine to gain insight into the
interstitial environment of the renal resistance vessels.
Methods
Experiments were performed on greyhounds weighing 24 to
32 kg (mean SE, 28.3 0.6) maintained on dog biscuits and
water. Furosemide (40 mg with food) was given 42 and 18 hr
before experiments; after the second dose, food and water were
withheld to ensure that the dogs became fluid- and salt-depleted
to enhance PG production [8, 191 and to augment the Cl-induced
renal vasoconstnction [15]. After inducing anesthesia with
pentobarbitol sodium, the trachea was intubated and a femoral
artery was cannulated for blood sampling. Measurement of
mean arterial pressure (MAP) was made using a pressure
transducer (Statham Instruments, Oxnard, California, USA).
Both kidneys were exposed through a midline abdominal inci-
sion. Two different kidney preparations were used.
Preparation 1: in situ kidney for collection of hilar lymph
Described in detail previously [14], this preparation was used
for all studies in which renal lymph was collected for PG
analysis. The left (experimental) kidney was mobilized and one
to three hilar lymphatic vessels were cannulated with PE10
polyethylene tubing (Intramedic OD 0.61 mm, Clay Adams,
Parsippany, New Jersey, USA). The carinulae were manipu-
lated past several valves (located at approximately 1-mm inter-
vals) and were secured in position with 8-0 silk ligatures. The
renal vein was cannulated via the gonadal vein. The renal artery
was doubly transfixed by an 18-gauge hooked needle whose tip
was blocked, but a new hole was bored in its shaft, preventing
the needle from becoming displaced [14]. Solution A was
delivered at 0.1 ml min kg body wF' through this needle; this
rate of infusion is less than 1% of renal blood flow. During
surgery, the dogs received 500 ml of iso-oncotic (6 g 100 m1')
dextran (average molecular weight 110,000) in 0.154 M NaCl
solution (Dextravan 110, Fisons Ltd., London, England). This
solution was also used to replace the blood withdrawn. Follow-
ing surgery, a solution of two-thirds 0.154 M NaCl solution and
one-third 1.10 M mannitol was infused intravenously at 0.04 ml
min' kg body wr' to maintain a basal urine flow of approxi-
mately 1 ml mint. The markers used to estimate GFR (51Cr-
ethylenediaminetetraacetic acid, Amersham Corp., Arlington
Heights, Illinois, USA) and renal plasma flow (RPF; I25j
hippuran, Amersham Corp.) were added to this infusion. Mea-
surements were begun 1 hr after surgery was completed.
There were three series of experiments using this prepara-
tion:
Series 1: intrarenal infusion of hypertonic saline (N = 6).
These experiments were designed to assess changes in renal
function and release of PGs or their derivatives during Cl-
induced renal vasoconstriction using a protocol described pre-
viously [15]. Dogs were given a 0.154 M NaC1 solution intraren-
ally (solution A) during a basal period (45 mm). Urine samples
were collected from the experimental and control kidneys and
lymph from the cannulated, hilar lymphatic vessels. At the
midpoint of the basal period, 15 ml blood samples were drawn
from the femoral artery and renal vein. Thereafter, the intrare-
nal infusion was changed to a 1.232 M NaCl solution. This rate
of infusion increases the renal arterial PNa and Pci by 10 to 15
mM and induces transient (1 to 2 mm) renal vasodilatation
followed by a progressive and sustained renal vasoconstriction
and a fall in GFR [15]. The second clearance period of 45 mm
commenced 30 mm after starting the hypertonic infusion to
correspond with the period of renal vasoconstriction. Urine and
renal lymph were collected on ice and 1-ml aliquots were frozen
for PG assay.
Series 2: intrarenal infusion of archidonic acid (N = 12).
These experiments were designed to study the effects of aug-
menting PG synthesis with AA on the renal function and release
of renal PGs. After baseline measurements of renal function and
PG release as in series 1, the intrarenal arterial infusion of 0.154
M NaC1 solution was changed to AA (4.5 mg m1'; Sigma
Chemical Company, St. Louis, Missouri, USA) in ethanol
dissolved in fresh, homologous dog's plasma (four studies) or
0.2% Na2CO3 (eight studies). In this series, the vehicle alone
was infused intrarenally during the baseline period. The AA
was dissolved most easily in the Na2CO3 solution, but since
similar results were obtained with the two vehicles, the data
were pooled. This rate of AA infusion was designed to achieve
a concentration of AA in renal arterial blood of approximately
5 zg m1'. After 30 mm of AA infusion, there was a 45-mm
period of urine and lymph collection with blood sampling at the
midpoint.
This protocol was selected after preliminary studies in four
dogs in which AA was infused intrarenally at 0.045, 0.45, and
4.5 mg mY1 (estimated concentrations in renal arterial blood
were 0.05, 0.5, and 5 pg ml, respectively). Each dose was
infused for 45 mm with clearance periods obtained over the last
30 mm. The mean values for RBF increased above baseline by
4, 12, and 26% at each dose; only at the highest dose was a
consistent increase in RBF seen in each dog and, therefore, this
dose was selected for the subsequent studies.
Series 3: intrarenal infusion of hypertonic saline during AA
(N = 11). These experiments were designed to determine
whether enhanced PG synthesis changed the hemodynamic
response to hypertonic NaCI infusions. Additionally, because
we found in protocol 1 that the concentrations of some PGs
were at, or close to, the limits of detection by our assay, we
used AA also to elevate PG concentrations. Accordingly, after
series 2 was completed, the intrarenal infusion of AA was
continued in these same dogs, but sodium chloride was added to
provide a 1.232 M NaCl solution. After a 30-mm period,
collections of urine and lymph were commenced as in series 1.
Preparation 2: autotranspianted kidney
With this preparation, the kidney is fully denervated and the
entire output of renal lymph can be collected. The experimental
kidney was autotransplanted to the neck of the same dog by
anastomosis to the carotid artery and jugular vein as described
in detail previously [20]. During preparation, hilar and capsular
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lymphatic vessels were incised. The artery supplying the kidney
was cannulated with an 18-gauge needle through which solution
A was infused at 2 ml min'. A tributary of the jugular vein was
cannulated to obtain samples of renal venous blood. Both
ureters were cannulated. The experimental kidney was placed
in a box filled with light liquid paraffin mineral oil and main-
tained at 37°C by a water jacket. Renal lymph issuing from the
incised lymphatic vessels was collected under the liquid paraffin
oil at the bottom corner of the box where it was aspirated via a
cannula, and its volume was measured gravimetrically. The
ureter of the contralateral kidney was cannulated, but this
kidney was otherwise undisturbed. Both kidneys were perfused
with homologous, arterial blood, except for 4 to 6 mm during
autotranspiantation when perfusion to the experimental kidney
was interrupted. Renal perfusion pressure, measured via the
needle in the renal artery, approximated closely to arterial
pressure in all dogs.
An equilibrium period of 1 hr was allowed after surgery
before plasma or lymph sampling. During surgery, the animals
received 15 ml kg body wt of 0.154 M NaC1 solution to replace
fluid losses [15]. The basal function of the experimental kidney
preparation and its relationship to the function of the contralat-
eral untouched kidney have been described previously [15, 201.
There were two series of experiments using the autotrans-
planted kidney preparation:
Series 4 and 5: intrarenal infusion of hypertonic Na acetate
followed by hypertonic NaCI. These studies were designed to
investigate the effects of an acute increase in plasma chloride
concentration (Pci) on RBF and total renal lymph flow (total
LFR) during a sustained increase in plasma sodium concentra-
tion (PNa) (series 4; N = 9). In parallel studies (series 5; N = 5),
dogs were treated with indomethacin before assessing the
response to hyperchloremia. The dose of indomethacin used
was shown in other studies in the dog to suppress TXB2
production and to reduce renal PG secretion into blood and
urine by greater than 70% [6, 8, 211. Dogs of both series
received a continuous intrarenal arterial infusion of 0.616 M Na
acetate at 0.2 ml min' kg body wt for 45 mm, which was
changed to an equally hypertonic solution of sodium chloride
for a further 45 mm. These rates of infusion increased the Pc1
and/or PNa of the renal arterial blood by 8 to 12 mmoles 11
above systemic arterial levels [15]. Measurements of total LFR
were made over the last 30 mm of each period and BP and RBF
made at 30 mm. For this series, mean RBF was recorded as the
electrically damped output from an electromagnetic blood flow
meter (Biotronex Laboratory, Inc., Kensington, Maryland,
USA); the probe encircled the artery supplying the experimen-
tal kidney about 2 inches proximal to the intra-arterial needle
[20].
No measurements of PGs or TXB2 were made in dogs of
series 4 and 5.
Laboratory methods
Details of the analytic methods have been described previ-
ously [14, 15, 20]. Na and K concentrations were measured
in a flame photometer (IL Flame Photometer), Cl- with a
chloride meter (Corning Medical, Corning Glassworks) and
osmolality (Osm) with an osmometer. Hematocrit (Hct) was
estimated as the mean of two measurements with a
microhematocrit centrifuge (Hawksley). Plasma solids concen-
tration (PS indicating plasma protein concentration) was esti-
mated by desiccating a weighed quantity of plasma to constant
weight and re-weighing with correction for the measured con-
tent of ions. The radioactivity of l-ml aliquots of arterial and
renal venous plasma and urine were counted with an
autogamma counter (Packard Instruments, Downers Grove,
Illinois, USA).
Prostaglandin assays
Prostacyclin is converted rapidly by a non-enzymic process
to 6ketoPGF1, (6kPGF1a) before further metabolism [3, 22] and
thromboxane is converted non-enzymically to TXB2 [2]. We
measured these degradation products because they are more
stable than the parent compounds. Renal excretion of 6kPGF1
correlates with the rate of prostacyclin infusion in the dog [3].
Since some urinary 6kPGF1a and TXB2 may derive from plasma
[23], we measured rates of PG excretion at the experimental and
control kidneys since the excretion of arterially borne PGs
should be similar at both kidneys. PGE2, PGF2a, 6kPGF1, and
TXB2 have been measured in plasma, urine, and lymph by
radioimmunoassay (RIA) or gas chromatography mass spec-
trometry (GCMS) methods [3, 6, 8, 9, 19, 23, 24, 35]. Both
methods may overestimate 6kPGF10, in plasma samples by
comparison with capillary column gas chromatography coupled
with negative ion chemical ionization mass spectrometry [26].
Although levels of TXB2 appear to be higher when assayed by
RIA than GCMS, the two methods show similar differences
between urine samples [9, 23]. Both RIA and GCMS have been
used to measure PGs and TXB2 in lymph [24, 25]. However, in
view of the unresolved methodologic problems in PG assay
(reviewed in detail recently [29]), we designed protocols to
permit within-dog comparisons of the effects of AA or
hyperchloremia on release of PGs into urine or lymph. We used
a RIA method to measure PGE2, PGF2a, 6kPGF1, and TXB2 in
extracted samples of urine and lymph [27, 28, 30]. This method
has been validated in our laboratory by comparison with GCMS
[28].
The assay samples (1 ml) of urine and lymph were acidified to
pH 3 and extracted twice with 2 volumes of diethyl ether; the
combined organic phases were dried under a stream of N2 and
redissolved in tricine-buffered saline (pH 8.0) for radio-
immunoassay [28]. Aliquots (100 l) of standard solutions of
PGs and unknowns were equilibrated at 4°C overnight with 3(H)
prostaglandins (100 d; approximately 15,000 DPM; 150 pCi
m1'; New England Nuclear Corp., Boston, Massachusetts,
USA) and rabbit anti-PG immunoglobulin (0.5 tgJl00 pJ1,
which binds approximately 50% of the label in the absence of
added PG). Antibody-bound label was precipiated using ammo-
nium sulphate, centrifuged at x lSOOg for 10 mm and redis-
solved in 0.45 ml of distilled water. One milliliter of instagel
(Packard Instruments) was added and the radioactivity deter-
mined. Immunoreactive PGs in the sample were estimated by
interpolation from standard displacement curves following cor-
rection for the counting efficiency using an external standard.
The specificity of the anti-sera used in these assays was
determined and is shown in Table 1.
Statistical methods
Results are presented as group means SEM. Unpaired I
tests are used for between-dog comparisons and paired t tests
46 Wilcox et at
Table 1. Cross reactivity of prostaglandins and arachidonic acid (%)
PGE2 PGF2 6ketoF1. TXB2
PGE2 100 0.03 0.001 0.02
PGF2, 1.4 100 0.4 0.1
6ketoF1 0.03 0.18 100 0.01
TXB2 0.04 <0.01 <0.001 100
AA 0.08 >0.001 0.002 0.002
for within-dog comparisons. The results obtained during the
infusion of AA with hypertonic saline (series 3) are compared to
those obtained in the same animal during the infusion of AA
alone (series 2).
Results
Basal PG concentrations and rates of release
All PGs, except PGF2, were detected in renal lymph and all
were detected in urine where their concentrations exceeded
that in lymph by about threefold. The rates of excretion of PUs
in urine were much higher than in lymph, reflecting the 20-fold
greater rate of urine flow. Neither the concentrations nor the
rates of excretion of any of the four PGs differed at the
experimental and contralateral kidneys (data not shown), indi-
cating that the exposure of the experimental kidney and can-
nulation of its lymphatic vessels had not caused any major
perturbations in its rate of PG excretion.
We collected renal lymph from the one to three largest hilar
lymphatic trunks; there remained some smaller hilar lymph
vessels and capsular vessels which were not sampled. The
average LFR obtained in this series was 3.61 0.65 p.l min'
kg', which is 76% of the value of total LFR that we measured
directly in the autotransplanted greyhound kidney in the basal
state [20].
Series 1: effects of infusion of hypertonic saline alone on
renal PGs. During the infusion of hypertonic sodium chloride
solution, the excretion of TXB2 into urine from the experimen-
tal kidney doubled (Table 2). This rise occurred in each dog and
was relatively specific for TXB2 because there were no consist-
ent changes in the release of the other PGs into urine from the
experimental kidney. However, there was a trend toward
increased excretion of PGE2 and PGF2. There were no changes
in excretion of any PG from the control kidney. Both the
concentration and the rate of release of TXB2 into renal lymph
also increased consistently during the infusion of hypertonic
sodium chloride, although the rise was modest. There were no
significant changes in the rates of release of other PGs into
lymph.
Series 2: effects of arachidonic acid on renal PGs. Intrarenal
infusion of AA led to a striking release of PGE2, 6kPGF1a, and
PGF2a into urine from the experimental kidney where excretion
rose three- to fivefold (Table 2); the excretion of TXB2 doubled.
There were no changes in excretion of PGs by the control
kidney except for an increase in 6kPGF1 (from 180 41 to 286
64 pg min' kg—'; P < 0.05).
AA led to a marked increase in the concentration of 6kPGF1a
in lymph (approximately tenfold increase), which clearly be-
came the predominant lymph PU; its concentration rose to
equal that in urine. While the release of PGE2 and PGF2a into
lymph doubled, there was no increase in the release of TXB2.
Series 3: effects of infusion of hypertonic saline during AA on
renal PGs. In pilot studies, AA (4.5 mg ml') was infused
intrarenally for 120 mm in two dogs and renal function and PG
excretion measured at 30 to 60 mm and at 90 to 120 mm.
Comparing these two periods, renal clearance data were steady.
The mean rates of PG excretion (pg min' kg') in the two
periods were: PGE2, 310 and 260; 6kPGF1a, 380 and 470;
PGF2, 170 and 180; and TXB2, 130 and 140. Thus, the rates of
PG excretion during an intrarenal AA infusion appeared to be
quite constant over this period.
The studies of series 3 followed on from those in series 2 by
maintaining the intrarenal infusion of AA but delivering it in a
hypertonic sodium chloride solution. When results from this
series are compared to those during infusion of AA alone in the
same dogs (series 2), there were no significant changes in the
rates of excretion of PGE2, 6kPGF1a, or PGF2. into urine (Table
2). Thus, the increased rates of excretion of these PGs above
basal values elicited by the prior infusion of AA were main-
tained when hypertonic sodium chloride was infused concur-
rently. However, the excretion of TXB2 showed a different
pattern. Thus, TXB2 excretion was not increased significantly
during AA infusion alone yet concurrent AA infusion with
hypertonic sodium chloride led to a three- to fivefold increase in
excretion. There were no significant changes in the excretion of
PGs by the contralateral kidney during series 3, compared to
series 2.
Considering the changes in the PG release into lymph, the
augmented release rate of PGE2, 6kPGF,, and PGF2 evoked
by the prior infusion of AA were maintained during concurrent
infusion of hypertonic sodium chloride (Table 2). Although the
release rates of these PG were all greater than during the basal
period, there were no significant changes during AA with
hypertonic sodium chloride compared to those recorded during
AA alone. In contrast, release of TXB2 into lymph was un-
changed by AA, but doubled when hypertonic sodium chloride
was infused concurrently with AA.
Effects of AA and hypertonic NaCI infusions on MAP and
renal function
Basal values for mean arterial pressure (MAP) and the
function of the experimental kidney were similar to a previous
series [14] and are shown in Table 3. The renal hemodynamics,
urine flow rate (V), excretion of Na and C1 and Uosm of the
experimental kidney did not differ significantly from the control
kidney.
Intrarenal infusion of AA reduced the MAP by approximately
7% (Table 3). While the GFR was unchanged, the RPF and RBF
increased by approximately 17%, leading to a significant fall in
filtration fraction (FF) and RVR of 20 to 30%. The excretion of
Na and Cl— were not changed, but there was a diuresis with a
decrease in UOsm and a reduction in negative free-water clear-
ance (CH,o) without a change in osmolar clearance (Cosm). The
LFR was unchanged and there were no significant changes in
the function of the control kidney.
Intrarenal infusion of hypertonic saline alone increased the
renal venous Pci by 13 3 mM. There was no change in MAP,
but GFR and RBF fell in each dog; the RVR increased by about
50% (Table 4). When the hypertonic saline was delivered during
a concurrent intrarenal infusion of AA, the initial RVR and FF
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Table 2. Prostaglandin concentrations and rates of release into urine and renal lympha
(A) Concentrations,
ng mg'
(B) Rates of release,
pg min' kg body wr'
Urine LymphUrine Lymph
PGE21'
Basal
(1) Change with HS alone
(2) Change with AA
(3) Change with HS during AA
3.24 0.54 (15) 0.70 0.27 (18)
—0.65 0.97 (5) +0.13 0.13 (5)
+5.60 1.23 (10)' +0.74 0.55 (12)
—1.74 0.92 (9) +0.15 0.29 (11)
165 31 1.89 0.81
+179 86 +0.43 0.41
+560 148 + 1.84 0.90
+145 148 +0.92 1.14
6kPGF,
Basal
(1) Change with HS alone
(2) Change with AA
(3) Change with HS during AA
2.92 0.55 (18) 0.80 0.40 (18)
—0.21 0.77 (6) +0.40 0.36 (6)
+4.09 1.31 (12)" +8.61 3.02 (12)'
—1.96 1.36(11) —3.70 1.86(11)
202 46 2.26 1.09
+15 44 + 1.32 1.20
+519 197' +13.11 403d
+27 200 —3.92 3.59
PGF2
Basal
(1) Change with HS alone
(2) Change with AA
(3) Change with HS during AA
1.31 0.27 (17) ND
+ 1.07 0.97 (5) ND
+3.05 0.92 (l2Y' +0.58 0.21 (12)'
—0.25 0.79(11) +0.23 0.19 (11)
82 21
+73 52
+340 131' + 1.30 0.57'
+109 103 +1.55 0.79
TXB2
Basal
(1) Change with HS alone
(2) Change with AA
(3) Change with HS during AA
0.54 0.12 (15) 0.14 0.04 (15)
+0.33 0.12 (6)' +0.04 0.01 (6)C
+0.53 0.10 (9) —0.03 0.04 (9)
+ 1.43 0.59 (8)' +0.10 0.05 (8)
39 12 0.28 0.09
+51 21' +0.13 0.05'
+38 12' —0.08 0.08
+325 144' +0.24 0.10'
Abbreviation: ND, not detected.
a The values are mean SEM (the number of observations in parentheses) for prostaglandin concentrations and release rates into urine and renal
lymph from the experimental kidney.
b In this column, values are shown for the basal state (combined data from all experiments) and changes produced by (1) the infusion of
hypertonic saline, (2) the infusion of arachidonic acid (AA), and (3) the infusion of hypertonic saline during continuous arachidonic acid infusion.
For this latter series, the changes refer to differences measured compared to those recorded during the AA infusion alone (HS during AA).
The significance of changes was assessed using a paired t test.
P < 0.05
d P < 0.01
P < 0.005
were lower and the increment in RVR produced by the
hypertonic sodium chloride, although significant, was reduced
to only 18%.
Relationships between changes in renal function and PG
release
AA infusion stimulated the release of PGE2 into renal lymph.
As shown in Figure 1, renal vasoconstriction during hypertonic
sodium chloride infusion was not seen in five dogs in which
lymph PGE2 release exceeded 2 pg min kg' before the
hypertonic sodium chloride infusion; in contrast, in 12 dogs in
which PGE2 release into lymph was below this level, the rise in
RVR always exceeded 2 mm Hg ml min' kg'.
To test the hypothesis that RVR could have been regulated
by a balance between the release of vasodilator and
vasoconstrictor PGs, data from the three series were pooled,
and the relationship between changes in RVR and the ratio of
excretion of vasodilator PGs (PGE2 plus 6kPGF1a) to TXB2 was
examined. As shown in Figure 2, there was a significant inverse
correlation (r = —0.74).
Series 4 and 5: changes in renal vascular resistance during
hyperchioremia—effects of indomethacin. The basal renal func-
tion of the autotransplanted kidney and its relationship to the in
situ kidney have been described previously [15, 201. Changing
the intrarenal-arterial infusion of 0.616 M Na acetate to 0.616 M
NaC1 reduced RBF in each of nine dogs, without consistent
changes in MAP. Consequently, RVR increased significantly
(from 13.5 1.8 to 19.3 1.6mm Hg ml min1 kg body wt1;
P < 0.001).
Administration of indomethacin increased RVR in each of
five dogs. Substitution of an intrarenal-arterial infusion of 0.616
M NaC1 for 0.616 M Na acetate in these indomethacin-
pretreated dogs increased RVR from 13.8 2.2 to 16.6 1.81.
This increase in RVR of 2.8 1.1 mm Hg m1' min' kg body
wr' appeared less (P = 0.05) than the Cl-induced increase of
5.8 0.9mm Hg m1' min' kg body wt1 in the dogs of series
4 in which indomethacin was not administered.
Discussion
The main findings were as follows: In the basal state, PGs
were released into the urine (PGE2 = 6kPGF1a > PGF2 >
TXB2), and all except PGF2 were detected in renal lymph.
Infusion of AA led to a fall in RVR and increased substantially
the release of vasodilator PGs (PGE2 and 6kPGF1) into urine
and renal lymph. Intrarenal infusions of hypertonic sodium
chloride led to renal vasoconstriction and a fall in GFR and
increased selectively the release of TXB2. A concurrent infu-
sion of AA maintained a high rate of release of vasodilator PGs.
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Table 3. Effects of intrarenal infusion of arachidonic acid on blood pressure and function of the experimental kidneya
Initial value Change P value
MAP, mm Hg 166 4 —11 3 <0.005
GFR, mlmin' kg' 1.63 0.13
—0.06 0.10 NS
RPF, ml min' kg' 6.19 0.55 + 1.08 0.47 <0.05
FF, % 27.8 2.1
—5.4 1.3 <0.005
RBF, ml min' kg' 12.80 1.26 +2.40 1.03 <0.05
RVR, mm Hg ml' min' kg' 15.2 2.5
—4.0 1.4 <0.02
V, pi mitr' kg' 68 8 +20 7 <0.02
UNaV, jxmoles min' kg' 4.66 1.11 —0.34 0.81 NS
U1V, p.moles mi,r' kg' 2.70 0.30 +0.25 0.19 NS
Uosm, mOsm kg' 563 47 —141 31 <0.001
Cosm,pjmin'kg' 111 7 —2 9 NS
CH2O, pi min' kg'
LFR, lmin' kg-' —44 63.61 0.65 +23+0.83 50.46 <0.001NS
Abbreviations: (see Results).
a The values represent the mean (± SEM) from 12 experiments (preparation I in the in situ kidney) showing initial values and changes produced
by intrarenal infusion of arachidonic acid into the experimental kidney (series 2).
Fig. 1. Relationship between changes in renal vascular resistance
during infusion hypertonic saline alone (series 1) or during concurrent
infusion of AA (series 3) and the measured rate of release of PGE2 into
renal lymph. Symbols are: A, 1.232 M NaCI; •, 1.232 M NaCI during
AA.
Renal vasoconstriction was abolished in those dogs with the
highest release rates of PGE2 into renal lymph. Renal vasocon-
striction during hyperchloremia was reduced, but not abol-
ished, in dogs receiving indomethacin.
PGE2, PGF2a, thromboxane, and prostacyclin can be pro-
duced in vitro in the cortex or by isolated glomeruli, but there
is also a substantial capacity for their synthesis in the medulla
[31—331. Detection of PGs in renal lymph does not prove cortical
synthesis since PGs formed in the medulla might migrate via the
vasa recta or tubular systems. However, lymphatic vessels are
distributed to the glomeruli, arterioles, and venules of the renal
cortex [17, 181 and, therefore, the finding of PGs in lymph
suggests that they are present in significant concentrations in
the interstitium in the vicinity of the major renal resistance
vessels.
Infusion of AA
The infusion of AA increased the release of PGE2, 6kPGF1,
and PGF2 into urine and lymph (although the changes for PGE2
in lymph were not significant). The most striking change was in
the release of 6kPGF1a into lymph where the concentration
increased about tenfold. This suggests that prostacyclin can be
released preferentially into a compartment which is close to
renal lymph. Renin also can be released into renal lymph where
its concentration exceeds that in renal venous blood severalfold
[20, 34]. Thus, prostacyclin and renin are produced in close
proximity in the renal cortex in vivo, as would be required if
prostacyclin were to modulate renal release [35]. During infu-
sion of AA there was an increase in excretion of 6kPGF1a by the
contralateral kidney also, albeit not to the levels seen at the
experimental kidney. This could represent formation of prosta-
cyclin from AA in the pulmonary circulation [21 with recircula-
tion and excretion of its derivative [31.
In contrast, infusion of AA had only minor effects on TXB2
excretion and no discernable effects on release of TXB2 into
renal lymph. PGE2 and prostacyclin are potent renal vasodila-
tors in the dog [1, 3, 4], whereas thromboxanes are potent
vasoconstrictors [5, 211. Thus, AA appeared to shift the balance
between vasodilator and vasoconstrictor PGs in the kidney,
which could underlie the marked decrease in RVR observed.
Infusion of hypertonic saline
In micropuncture studies, the blood flow and GFR of a
nephron have been related to the rate of sodium chloride
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Table 4. Effects of 1.232 M NaCI infusions on BP and renal functiona
(B) Intrarenal
(A) Intrarenal 1.232 M NaC1 during Differences between
1.232 M NaC1 Alone intrarenal AA A and B(N = 6) (N = II) Pvalue
MAP, mm Hg Before
Change
162 3
—1
155 5
0
NS
NS
GFR, ml min' kg-I Before
Change
1.32 0.14
—0.28 0.06
P<0.005
1.56 0.16
—0.21 0.07
P<0.02
NS
NS
RBF, ml miir1 kg' Before
Change
9.09 0.80
—2.83 0.28
P < 0.001
15.28 1.67
—2.56 1.13
P < 0.05
<0.005
NS
FF, % Before
Change
30.6 2.9
+0.7 1.8
22.4 2.1
—0.3 1.1
<0.05
NS
RVR, mm Hg mt' min' kg-I Before
Change
18.83 1.72
+9.81 1.93
P<0.001
11.5 1.3
+2.1 0.7
P<0.02
<0.005
<0.005
Abbreviations: (see Results).
a The mean (± 5EM) values were recorded before and the mean changes during intrarenal infusions of hypertonic sodium chloride solutions in
preparation I in the in situ kidney.
reabsorption at its macula densa segment. This TG response
involves an increase in afferent and efferent arteriolar resist-
ances and a fall in the glomerular ultrafiltration coefficient [36].
An intrarenal infusion of hypertonic sodium chloride can be
used to study this process at the whole kidney level because,
like the micropuncture model, renal vasoconstriction depends
on a rise in plasma C1 concentration (Pci), is augmented by
prior ECV depletion, is independent of the renal nerves, is
specific for the renal circulation [14, 15], and is abolished by
inhibition of loop sodium chloride reabsorption with furosemide
[161. The present results provide further evidence for a critical
role for independent of PNa or POsm since renal vasoconstric-
tion occurred in dogs of series 4 when an intrarenal infusion of
hypertonic Na acetate was changed to hypertonic sodium
chloride. The signal generated by changes in C1 loading may
be an alteration in PG synthesis. Thus, our present results
confirm previous findings in the dog [16] that indomethacin
reduces, but does not abolish, sodium chloride-induced renal
vasoconstriction. In the rat, indomethacin can abolish the TG
response, although the response can be restored by infusion of
PGE2 or prostacyclin [13]. The present results suggest that a
vasoconstrictor PG, thromboxane, may be released during the
TG response since we found a consistent increase in release of
TXB2 into urine and lymph during Cl-induced renal vasocon-
striction. Despite this circumstantial evidence, it is important to
state that a causal relationship between Cl-induced generation
of TX and renal vasoconstriction has not been established in
these studies. The model in which indomethacin was found to
blunt Cl-induced renal vasoconstriction (series 4 and 5) differed
slightly from that in which a Cl-induced rise in release of TXB2
was demonstrated (series Ito 3). Moreover, TXB2 was the least
abundant PG, both in urine and lymph. Studies with TX
synthesis antagonists will be required to define the functional
significance of TX in Cl-induced vasoconstriction.
The observation that concurrent infusion of AA diminished
the Cl-induced renal vasoconstriction could be attributed to the
Fig. 3. Mean (± SEM) values of renal vascular resistance and excretion
of 6ketoPGFja and TXB2. Data in the left panel are from series I
showing values obtained in the basal state and during the infusion of
hypertonic saline. Data in the right panel are from series 2 and 3
showing values obtained in the basal state, during the infusion of
arachidonic acid, and during the infusion of hypertonic saline plus
arachidonic acid.
high rate of ongoing AA-stimulated synthesis of vasodilator
PGs. As shown in Figure 3, high rates of excretion of 6kPGF1a
induced by AA persisted during a concurrent infusion of
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hypertonic sodium chloride, suggesting that ongoing renal
prostacyclin production may have limited the vasoconstrictive
effect of any TX released. The results also indicate a potential
role for AA-induced release of POE2 in countering Cl-induced
renal vasoconstriction since RVR did not increase in series 3
during infusion of hypertonic sodium chloride in those dogs
with the highest rates of release of PGE2 into renal lymph (Fig. 1).
Overall, there was a significant correlation in these studies be-
tween changes in RVR induced by an infusion of hypertonic saline or
AA and the ratio of excretion of POE2 plus 6kPGF1, to TXB2. The
results show that the release of vasodilator and vasoconstrictor PGs
within the kidney can be regulated relatively selectively and indicate
that the balance between these two PG systems may be important in
modulating RVR and the TO response.
Acknowledgments
This work was supported by a Senior Clinical Fellowship award from
the Welicome Trust to CSW and by grants AM34825 and AM27952 from
the National Institutes of Health and the Veterans Administration,
Washington, D.C. (G.R.E.C.). We thank P. Dolan for preparing the art
work and manuscript and B. Taylor for technical assistance.
Reprint requests to Dr. C. S. Wilcox, Division of Nephrology and
Hypertension, Box J-224, JHMHC, University of Florida, Gainesville,
Florida 32610—0224 USA
References
1. TANNENBAUM J, SPLAWINSKI, JA, OATES JA, NIES AS: Enhanced
renal prostaglandin production in the dog. I. Effects on renal
function. Circ Res 36:197—203, 1975
2. MULLANE KM, DUSTING GJ, SALMON JA, MONCADA S, VANE JR:
Biotransformation and cardiovascular effects of arachidonic acid in
the dog. Eur J Pharmacol 54:217—228, 1979
3. BRYDON U, JONES RL, WATSON ML: The relationship between
PGI2 infusion rate, blood pressure, renal function and urinary
6-keto-PGF1 excretion in conscious dogs. BrJ Pharmacol 1985, in
press
4. GERBER JG, NIE5 AS, FRIESINGER GC, GERKENS JF, BRANCHRA,
OATES JA: The effects of PGL2 on canine renal function and
hemodynamics. Prostaglandins 16:519—528, 1978
5. FRIEDMAN LS, FITZPATRICK TM, BLOOM MF, RAMWELL PW,
ROSE JC, KOT PA: Cardiovascular and pulmonary effects of
thromboxane B2 in the dog, Circ Res 44:748—751, 1979
6. AIKEN JW, VANE JR: Intrarenal prostaglandin release attenuates
the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp
Ther 184:678—687, 1973
7. Nrns AS, RAWL J, CRUZE J, OATES JA, FROLICH JC: The impor-
tance of renal prostaglandin synthesis in maintaining renal blood
flow and glomerular filtration after renal artery stenosis in the
conscious dog. Invest Urol 16:72—74, 1978
8. OLIVER JA, PINTO J, SCIACCA RR, CANON PJ: Increased renal
secretion of norepinephrine and prostaglandin E2 during sodium
depletion in the dog. J Cliii Invest 66:748—756, 1980
9. ZIPSER RA, RADVAN GH, KRONBORG IJ, DUKE R, LITTLE TE:
Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal
syndrome: evidence for increased vasoconstrictor and decreased
vasodilator factors. Gastroenterology 84:697—703, 1983
10. YARGER WE, SCHOCKEN DD, HARRIS RH: Obstructive nephrop-
athy in the rat: possible roles for the renin-angiotensin system,
prostaglandins and thromboxane in postobstructive renal function.JClin Invest 65:400-412, 1980
11. LIANOS EA, ANDRES GA, DUNN MJ: Glomerular prostaglandin
and thromboxane synthesis in rat nephrotoxic serum nephritis.
Effects on renal hemodynamics. J Clin Invest 72:1439-1448, 1983
12. SHIBOUTA Y, INADA Y, TERASHITA Z, NISHIKAWA K, KIKUCHI 5,
SHIMAMOTO K: Angiotensin Il-stimulated release of thromboxane
A2 and prostacyclin (PGI2) in isolated, perfused kidneys of sponta-
neously hypertensive rats. Biochem Pharmacol 28:3601—3609, 1979
13. SCHNERMANN G, SCHUBERT G, HERMLE M, HERBST R, STOWE
NT, YARIMIZU S, WEBER PC: The effect of inhibition of
prostaglandin synthesis on tubuloglomerular feedback in the rat
kidney. Pflugers Arch 379:269—279, 1979
14. NASHAT FS, TAPPIN JW, WILcox CS: The renal blood flow and the
glomerular filtration rate of anesthetized dogs during acute changes
in plasma sodium concentration. J Physiol 256:731—746, 1976
15. WILCOX CS: Regulation of renal blood flow by plasma chloride. J
Clin Invest 71:726—735, 1983
16. GERBER JG, BRANCH RA, NIEs AS, HOLLIFIELD JW, GERKENS JF:
Influence of hypertonic saline on canine renal blood flow and renin
release. Am J Physiol 237:F441—F446, 1979
17. ALBERTINE KH, O'MORCHOE CCC: Distribution and density of the
canine renal cortical lymphatic system. Kidney mt 16:470—480, 1979
18. BELL RD, KEYL MJ, SHRADER FR, JONES EW, HENRY LP: Renal
lymphatics: The internal distribution. Nephron 5:454—463, 1968
19. CAMPBELL WB, HOLLAND OB, ADAMS By, GOMEZ-SANCHEZ CE:
Urinary excretion of prostaglandin E2, prostaglandin F2, and
thromboxane B2 in normotensive and hypertensive subjects on
varying sodium intakes. Hypertension 4:735—741, 1982
20. WILcox CS: The effect of increasing the plasma magnesium con-
centration on renin release from the dog's kidney: interactions with
calcium and sodium. J Physiol 284:203—217, 1978
21. UTSUNOMIYA T, KRAUSZ MM, LEVINE L, SHEPRO D, HECHTMAN
HB: Thromboxane mediation of cardiopulmonary effects of embo-
lism. J Clin Invest 70:361—368, 1982
22. GRIFFITHS RJ, MOORE PK: Formation of 6-keto prostaglandin E1 in
mammalian kidney. Br J Pharmacol 79:149—155, 1983
23. ZIPSER RD, MARTIN K: Urinary excretion of arterial blood prosta-
glandins and thromboxanes in man. Am J Physiol 242:El71—El77,
1982
24. SNAPPER JR. HUTCHISON AA, OGLETREE ML, BRIGHAM KL:
Effects of cyclooxygenase inhibitors on the alteration in lung
mechanics caused by endotoxemia in the unanesthetized sheep. J
Clin Invest 72:63—76, 1983
25. FROHLICH JE, OGLETREE ML, BRIGHAM KL: Pulmonary hyper-
tension correlated to pulmonary thromboxane synthesis, in Ad-
vances in Prostaglandin and Thromboxane Research, edited by
SAMUELSSON B, RAMWELL TW, PAOLETTI R, New York, Raven
Press, vol 7, 1980, pp 745—750
26. BLAIR IA, BARROW SE, WADDELL KA, LEWIS PJ, DOLLERY CT:
Prostacyclin is not a circulating hormone in man. Prostaglandins
23:579—589, 1982
27. JOSE PJ, PAGE DA, WILSTENHOLME BE, WILLIAMS Ti, DUMONDE
DC: Bradykinin-stimulated prostaglandin E2 production by
endothelial cells and its modulation by anti-inflammatory com-
pounds. Inflammation 5:363—378, 1981
28. BRODIE MJ, HENSBY CN, PARKE A, GORDON D: Is prostacyclin the
major pro-inflammatory prostanoid in joint fluid? Life Sci
27:603—608, 1980
29. FITZGERALD GA, PEDERSEN AK, PATRONO G: Analysis of
prostacyclin and thromboxane biosynthesis in cardiovascular dis-
ease. Circulation 67:1174—1177, 1983
30. HENSBY CN, JOGEE M, ELDER MG, MYATT L: A comparison of
the quantitative analysis of 6-oxo-PGF1,, in biological fluids by gas
chromatography mass spectrometry and radioimmunoassay. Bio
Mass Spect 8:111—1 17, 1981
31. HASSID A, KONIECZKOWSKI M, DUNN MJ: Prostaglandin synthesis
in isolated rat kidney glomeruli. Proc Nat! Acad Sci 76:1155—1159,
1979
32. PETRULIS AS, AIKAWA M, DUNN Mi: Prostaglandin and throm-
boxane synthesis by rat glomerular epithelial cells. Kidney Int
20:469—474, 1981
33. SMITH WL, BELL TG: Immunohistochemical localization of the
prostaglandin-forming cyclooxygenase in renal cortex. Am J Phys-
iol 235:F45l—F457, 1978
34. LEVER AF, PEART WS: Renin and angiotensin-like activity in renal
lymph, J Physiol 160:548—563, 1962
35. BEIERWALTES WH, SCHRYVER S, SANDERS E, STRAND J, ROMERO
JC: Renin release selectively stimulated by prostaglandin 12 in
isolated rat glomeruli. Am J Physiol 243:F276—F283, 1982
36. ICHIKAWA I: Direct analysis of the effector mechanism of the
tubuloglomerular feedback system. Am J Physiol 243:F447—F455,
1982
